About
News
Calendar
Education & Training
Careers
How to Help
Contact Us
My Dana-Farber
Español
Find a Doctor
Get Directions
For Physicians
Make a Gift
Adult Care
Treatment and Care
Treatment Centers and Clinical Services
Care Team
Patient And Family Support
Care Quality and Patient Safety
Patient Stories
For Adult Cancer Survivors
Browse by Cancer Type
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
New Patient Guide
Planning a Visit
Driving Directions
Parking at Dana-Farber
Maps of Dana-Farber
Preparing for Your First Visit
How to Prepare
Talking to Your Doctor
Financial and Legal Matters
Insurance and Financial Assistance
Your Role as Patient
Ethics Consultation
Health Care Proxy
Special Assistance
Interpreters
Patient Navigators
Disability Services
Patient Safety and Advocacy
Safety Information
Patient Relations
Adult Patient and Family Advisory Council
Legislative Action Network
Amenities and Resources
Concierge Services
Appointments & Second Opinions
New Patient?
For appointments or second opinions:
Adults:
(877) 442-DFCI (442-3324)
Children:
(888) PEDI-ONC (733-4662)
or complete the
Appointment Request Form
Online Specialty Consultations
International Patients
Referring Physician?
To refer an adult patient:
(877) 441-DFCI (441-3324)
To refer a pediatric patient:
(888) PEDI-ONC (733-4662)
or complete the
Patient Referral Form
Pediatric Care
Treatment and Care
Pediatric Treatment Centers and Clinical Services
Care Team
Patient And Family Support
Care Quality and Patient Safety
Patient Stories
For Survivors of Childhood Cancer
Browse by Cancer Type
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
New Patient Guide
Planning a Visit
Driving Directions
Parking at Dana-Farber
Maps of Dana-Farber
Preparing for Your First Visit
How to Prepare
Talking to Your Child's Doctor
Financial and Legal Matters
Insurance and Financial Assistance
Your Role as Patient
Ethics Consultation
Health Care Proxy
Special Assistance
Interpreters
Disability Services
Patient Safety and Advocacy
Safety Information
Patient Relations
Legislative Action Network
Pediatric Patient and Family Advisory Council
Amenities and Resources
Concierge Services
Appointments & Second Opinions
New Patient?
For appointments or second opinions:
Adults:
(877) 442-DFCI (442-3324)
Children:
(888) PEDI-ONC (733-4662)
or complete the
Appointment Request Form
Your Child's Care Team
For International Patients
Referring Physician?
To refer an adult patient:
(877) 441-DFCI (441-3324)
To refer a pediatric patient:
(888) PEDI-ONC (733-4662)
or complete the
Patient Referral Form
Research
Clinical Trials
Research Advances
Featured Research
Departments and Centers
Integrative Research Centers
Core Facilities
Research Administration
Technology Transfer
Find a Researcher
Health Library
Blog
Home
Research
Clinical Trials
Clinical Trials by Diagnosis
Leukemia/MDS Clinical Trials
Showing 31-38 of 38 items
Previous
1
2
31.
Safety and Tolerability of AZD1208 and the Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients
The purpose of this open label study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AZD1208 in patients with recurrent or refractory Acute Myelogenous Leukemia (AML). This study will have two parts. In Part A, patients will receive escalating doses to identify the maximum tolerated dose (MTD). In Part B, the efficacy of the maximum tolerated dose will be evaluated in a expanded group of patients with selected biomarker.
Diagnoses:
Leukemia/MDS
Status:
Recruiting
32.
Reduced Intensity Conditioning Versus Myeloablative Conditioning for Acute Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
The study is designed as a Phase III, multicenter trial comparing outcomes after allogeneic hematopoietic stem cell transplantation (HCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) between patients receiving myeloablative conditioning (MAC) versus reduced intensity conditioning (RIC) regimens.
Diagnoses:
Leukemia/MDS
Status:
Recruiting
33.
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Ref
This is a Phase I, multicenter, open-label, dose-escalation study of DCDT2980S administered by intravenous (IV) infusion to patients with relapsed or refractory hematologic malignancies. In addition, at selected sites, DCDT2980S will be studied in combination with rituximab.
Diagnoses:
Leukemia/MDS
,
Non-Hodgkin's Lymphoma
Status:
Recruiting
34.
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544.
Diagnoses:
Leukemia/MDS
Status:
Recruiting
35.
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
The purpose of this research study are to find out more information such as: the highest dose of KPT-330 that can be given safely, the side effects it may cause, to examine how the body affects the study drug concentrations in the blood (pharmacokinetics or PK), to examine the effects of this study drug on the body (pharmacodynamics or PDn) and to gain some information on its effectiveness in treating cancer.
Diagnoses:
Leukemia/MDS
Status:
Recruiting
36.
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This is a multi-center, open-label, dose escalation study.
Diagnoses:
Leukemia/MDS
Status:
Recruiting
37.
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin versus investigator's choice of chemotherapy.
Diagnoses:
Leukemia/MDS
Status:
Recruiting
38.
A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion
Diagnoses:
Leukemia/MDS
Status:
Recruiting
Showing 31-38 of 38 items
Previous
1
2
Email
Print
Share
Text
Highlight Glossary Terms